Literature DB >> 1671871

Genomic determination of the CR1 (CD35) density polymorphism on erythrocytes using polymerase chain reaction amplification and HindIII restriction enzyme digestion.

P Cornillet1, F Philbert, M D Kazatchkine, J H Cohen.   

Abstract

The density of CR1 (the C3b receptor, CD35) on erythrocytes from normal individuals is determined by a codominant bi-allelic system associated with a single base mutation within an intron of the CR1 structural gene, leading to an additional polymorphic HindIII endonuclease site. The CR1 genotype is determined by HindIII digestion of genomic DNA and Southern blotting. We have developed a method based on polymerase chain reaction (PCR) amplification of the genomic DNA fragment of interest followed by HindIII endonuclease digestion and agarose gel electrophoresis which permits a more rapid and reliable determination of the CR1 genotype. The method is suitable for large scale clinical studies in diseases with altered expression of CR1 on erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1671871     DOI: 10.1016/0022-1759(91)90006-2

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  9 in total

1.  Genomic determination of CR1 CD35 density polymorphism on erythrocytes of patients with gallbladder carcinoma.

Authors:  Xing-Yuan Jiao; Ming-De Lü; Jie-Fu Huang; Li-Jian Liang; Jing-Sen Shi
Journal:  World J Gastroenterol       Date:  2004-12-01       Impact factor: 5.742

2.  Regulation of circulating immune complexes by complement receptor type 1 on erythrocytes in chronic viral liver diseases.

Authors:  J Miyaike; Y Iwasaki; A Takahashi; H Shimomura; H Taniguchi; N Koide; K Matsuura; T Ogura; K Tobe; T Tsuji
Journal:  Gut       Date:  2002-10       Impact factor: 23.059

3.  A complement receptor-1 polymorphism with high frequency in malaria endemic regions of Asia but not Africa.

Authors:  B N Thomas; B Donvito; I Cockburn; T Fandeur; J A Rowe; J H M Cohen; J M Moulds
Journal:  Genes Immun       Date:  2005-02       Impact factor: 2.676

4.  Complement receptor 1 and the molecular pathogenesis of malaria.

Authors:  Monika Gandhi
Journal:  Indian J Hum Genet       Date:  2007-05

5.  Acquired but reversible loss of erythrocyte complement receptor 1 (CR1, CD35) and its longitudinal alteration in patients with severe acute respiratory syndrome.

Authors:  F S Wang; F L Chu; L Jin; Y G Li; Z Zhang; D Xu; M Shi; H Wu; J-M Moulds
Journal:  Clin Exp Immunol       Date:  2005-01       Impact factor: 4.330

6.  Human genetic polymorphisms in the Knops blood group are not associated with a protective advantage against Plasmodium falciparum malaria in Southern Ghana.

Authors:  Helle H Hansson; Jørgen A Kurtzhals; Bamenla Q Goka; Onike P Rodriques; Francis N Nkrumah; Thor G Theander; Ib Christian Bygbjerg; Michael Alifrangis
Journal:  Malar J       Date:  2013-11-07       Impact factor: 2.979

7.  High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment.

Authors:  Aymric Kisserli; Thierry Tabary; Jacques Henri Max Cohen; Valérie Duret; Rachid Mahmoudi
Journal:  J Vis Exp       Date:  2017-07-18       Impact factor: 1.355

8.  Inherited and Acquired Decrease in Complement Receptor 1 (CR1) Density on Red Blood Cells Associated with High Levels of Soluble CR1 in Alzheimer's Disease.

Authors:  Rachid Mahmoudi; Sarah Feldman; Aymric Kisserli; Valérie Duret; Thierry Tabary; Laurie-Anne Bertholon; Sarah Badr; Vignon Nonnonhou; Aude Cesar; Antoine Neuraz; Jean Luc Novella; Jacques Henri Max Cohen
Journal:  Int J Mol Sci       Date:  2018-07-25       Impact factor: 5.923

9.  High Incidence of Malaria Along the Sino-Burmese Border Is Associated With Polymorphisms of CR1, IL-1A, IL-4R, IL-4, NOS, and TNF, But Not With G6PD Deficiency.

Authors:  Na Ren; Ying-Min Kuang; Qiong-Lin Tang; Long Cheng; Chun-Hua Zhang; Zao-Qing Yang; Yong-Shu He; Yue-Chun Zhu
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.